Global Liver Disease Treatment Market

Liver Disease Treatment Comprehensive Study by Application (Hospital, Clinic, Others), Disease Type (Hepatitis, Autoimmune diseases, Liver tumor, Chronic liver disease, Fatty liver disease.), Treatment Type (Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, IImmunoglobulins, Corticosteroids) Players and Region - Global Market Outlook to 2030

Liver Disease Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Liver Disease Treatment
Liver disease is characterized by improper functioning of the liver, causing disorders like hepatitis, fatty liver, & cirrhosis. Some of the major drug categories used in the treatment of various types of liver diseases include antirejection drugs, vaccines, immuno suppressant, chemotherapy drugs, & antiviral drugs. The growth of the global liver disease treatment market is driven by an increasing prevalence of liver diseases, due to increasing consumption of alcohol & unhealthy diets, along with an increase in geriatric population & the rise of government & non-government awareness programs.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The prominent players in the liver disease treatment market have adopted strategies such as innovative product launch, merger & acquisition, partnership and business expansion to gain maximum market share. Analyst at AMA Research estimates that United states and European Players will contribute the maximum growth to Global Liver Disease Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Laboratories (United States), Actavis (United States), Aton Pharma (United States), Bayer Schering AG (Germany), Biotest (Germany), Bristol-Myers Squibb (United States), Eli Lilly ( United States), Forest Laboratories (United States), GlaxoSmithkline (United Kingdom), Gilead Sciences (United States), Merck & Co. (United States), Mylan (United States) and Novartis (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Pfizer (United States), Roche (Switzerland) and Takeda Pharmaceuticals (Japan).

Segmentation Overview
AMA Research has segmented the market of Global Liver Disease Treatment market by , Application (Hospital, Clinic and Others) and Region.



On the basis of geography, the market of Liver Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease Type, the sub-segment i.e. Hepatitis will boost the Liver Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Anti-Rejection Drugs/Immunosupressants will boost the Liver Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Use of Hybrid Systems For Imaging and Increasing R&D investments for the development of novel therapies

Market Growth Drivers:
Increasing prevalence of liver diseases and Growing geriatric population, Increasing government and non-government awareness programs and Rapidly changing lifestyle patterns such as increasing consumption of alcohol, and unhealthy diets

Challenges:
Side effect associated with medication

Restraints:
Stringent government regulations and High cost incurred in drug R&D

Opportunities:
Increasing Healthcare Expenditures In Emerging Markets and Availability of generic and bio-similar drugs

Market Leaders and their expansionary development strategies
In January 2023, Ipsen and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases. The anticipated acquisition will enrich Ipsen’s Rare Disease portfolio and pipeline.
In January 2023,Takeda and Arrowhead Pharmaceuticals Inc. announced topline results from the Phase 2 SEQUOIA clinical study of investigational Fazirsiran for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD). Source: https://www.mordorintelligence.com/industry-reports/liver-diseases-therapeutics-market


Key Target Audience
Treatment providers, Treatment Equipment manufacturer, Industry Association, Governments and investment communities, Research organizations and associations and End users (Hospitals and clinics)

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospital
  • Clinic
  • Others
By Disease Type
  • Hepatitis
  • Autoimmune diseases
  • Liver tumor
  • Chronic liver disease
  • Fatty liver disease.

By Treatment Type
  • Anti-Rejection Drugs/Immunosupressants
  • Chemotherapy Drugs
  • Targeted therapy
  • Vaccines
  • Anti-Viral Drugs
  • IImmunoglobulins
  • Corticosteroids

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of liver diseases and Growing geriatric population
      • 3.2.2. Increasing government and non-government awareness programs
      • 3.2.3. Rapidly changing lifestyle patterns such as increasing consumption of alcohol, and unhealthy diets
    • 3.3. Market Challenges
      • 3.3.1. Side effect associated with medication
    • 3.4. Market Trends
      • 3.4.1. Increasing Use of Hybrid Systems For Imaging
      • 3.4.2. Increasing R&D investments for the development of novel therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Liver Disease Treatment, by Application, Disease Type, Treatment Type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Liver Disease Treatment (Value)
      • 5.2.1. Global Liver Disease Treatment by: Application (Value)
        • 5.2.1.1. Hospital
        • 5.2.1.2. Clinic
        • 5.2.1.3. Others
      • 5.2.2. Global Liver Disease Treatment by: Disease Type (Value)
        • 5.2.2.1. Hepatitis
        • 5.2.2.2. Autoimmune diseases
        • 5.2.2.3. Liver tumor
        • 5.2.2.4. Chronic liver disease
        • 5.2.2.5. Fatty liver disease.
      • 5.2.3. Global Liver Disease Treatment by: Treatment Type (Value)
        • 5.2.3.1. Anti-Rejection Drugs/Immunosupressants
        • 5.2.3.2. Chemotherapy Drugs
        • 5.2.3.3. Targeted therapy
        • 5.2.3.4. Vaccines
        • 5.2.3.5. Anti-Viral Drugs
        • 5.2.3.6. IImmunoglobulins
        • 5.2.3.7. Corticosteroids
      • 5.2.4. Global Liver Disease Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Liver Disease Treatment (Price)
  • 6. Liver Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Actavis (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Aton Pharma (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer Schering AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Biotest (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly ( United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Forest Laboratories (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithkline (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Gilead Sciences (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Merck & Co. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Mylan (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Novartis (Switzerland)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Liver Disease Treatment Sale, by Application, Disease Type, Treatment Type and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Liver Disease Treatment (Value)
      • 7.2.1. Global Liver Disease Treatment by: Application (Value)
        • 7.2.1.1. Hospital
        • 7.2.1.2. Clinic
        • 7.2.1.3. Others
      • 7.2.2. Global Liver Disease Treatment by: Disease Type (Value)
        • 7.2.2.1. Hepatitis
        • 7.2.2.2. Autoimmune diseases
        • 7.2.2.3. Liver tumor
        • 7.2.2.4. Chronic liver disease
        • 7.2.2.5. Fatty liver disease.
      • 7.2.3. Global Liver Disease Treatment by: Treatment Type (Value)
        • 7.2.3.1. Anti-Rejection Drugs/Immunosupressants
        • 7.2.3.2. Chemotherapy Drugs
        • 7.2.3.3. Targeted therapy
        • 7.2.3.4. Vaccines
        • 7.2.3.5. Anti-Viral Drugs
        • 7.2.3.6. IImmunoglobulins
        • 7.2.3.7. Corticosteroids
      • 7.2.4. Global Liver Disease Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Liver Disease Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Liver Disease Treatment: by Application(USD Million)
  • Table 2. Liver Disease Treatment Hospital , by Region USD Million (2018-2023)
  • Table 3. Liver Disease Treatment Clinic , by Region USD Million (2018-2023)
  • Table 4. Liver Disease Treatment Others , by Region USD Million (2018-2023)
  • Table 5. Liver Disease Treatment: by Disease Type(USD Million)
  • Table 6. Liver Disease Treatment Hepatitis , by Region USD Million (2018-2023)
  • Table 7. Liver Disease Treatment Autoimmune diseases , by Region USD Million (2018-2023)
  • Table 8. Liver Disease Treatment Liver tumor , by Region USD Million (2018-2023)
  • Table 9. Liver Disease Treatment Chronic liver disease , by Region USD Million (2018-2023)
  • Table 10. Liver Disease Treatment Fatty liver disease. , by Region USD Million (2018-2023)
  • Table 11. Liver Disease Treatment: by Treatment Type(USD Million)
  • Table 12. Liver Disease Treatment Anti-Rejection Drugs/Immunosupressants , by Region USD Million (2018-2023)
  • Table 13. Liver Disease Treatment Chemotherapy Drugs , by Region USD Million (2018-2023)
  • Table 14. Liver Disease Treatment Targeted therapy , by Region USD Million (2018-2023)
  • Table 15. Liver Disease Treatment Vaccines , by Region USD Million (2018-2023)
  • Table 16. Liver Disease Treatment Anti-Viral Drugs , by Region USD Million (2018-2023)
  • Table 17. Liver Disease Treatment IImmunoglobulins , by Region USD Million (2018-2023)
  • Table 18. Liver Disease Treatment Corticosteroids , by Region USD Million (2018-2023)
  • Table 19. South America Liver Disease Treatment, by Country USD Million (2018-2023)
  • Table 20. South America Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 21. South America Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 22. South America Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 23. Brazil Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 24. Brazil Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 25. Brazil Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 26. Argentina Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 27. Argentina Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 28. Argentina Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 29. Rest of South America Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 30. Rest of South America Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 31. Rest of South America Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 32. Asia Pacific Liver Disease Treatment, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 34. Asia Pacific Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 35. Asia Pacific Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 36. China Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 37. China Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 38. China Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 39. Japan Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 40. Japan Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 41. Japan Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 42. India Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 43. India Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 44. India Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 45. South Korea Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 46. South Korea Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 47. South Korea Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 48. Taiwan Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 49. Taiwan Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 50. Taiwan Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 51. Australia Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 52. Australia Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 53. Australia Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 57. Europe Liver Disease Treatment, by Country USD Million (2018-2023)
  • Table 58. Europe Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 59. Europe Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 60. Europe Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 61. Germany Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 62. Germany Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 63. Germany Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 64. France Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 65. France Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 66. France Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 67. Italy Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 68. Italy Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 69. Italy Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 70. United Kingdom Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 71. United Kingdom Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 72. United Kingdom Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 73. Netherlands Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 74. Netherlands Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 75. Netherlands Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 76. Rest of Europe Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 77. Rest of Europe Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 78. Rest of Europe Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 79. MEA Liver Disease Treatment, by Country USD Million (2018-2023)
  • Table 80. MEA Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 81. MEA Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 82. MEA Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 83. Middle East Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 84. Middle East Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 85. Middle East Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 86. Africa Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 87. Africa Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 88. Africa Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 89. North America Liver Disease Treatment, by Country USD Million (2018-2023)
  • Table 90. North America Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 91. North America Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 92. North America Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 93. United States Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 94. United States Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 95. United States Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 96. Canada Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 97. Canada Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 98. Canada Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 99. Mexico Liver Disease Treatment, by Application USD Million (2018-2023)
  • Table 100. Mexico Liver Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 101. Mexico Liver Disease Treatment, by Treatment Type USD Million (2018-2023)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Liver Disease Treatment: by Application(USD Million)
  • Table 116. Liver Disease Treatment Hospital , by Region USD Million (2025-2030)
  • Table 117. Liver Disease Treatment Clinic , by Region USD Million (2025-2030)
  • Table 118. Liver Disease Treatment Others , by Region USD Million (2025-2030)
  • Table 119. Liver Disease Treatment: by Disease Type(USD Million)
  • Table 120. Liver Disease Treatment Hepatitis , by Region USD Million (2025-2030)
  • Table 121. Liver Disease Treatment Autoimmune diseases , by Region USD Million (2025-2030)
  • Table 122. Liver Disease Treatment Liver tumor , by Region USD Million (2025-2030)
  • Table 123. Liver Disease Treatment Chronic liver disease , by Region USD Million (2025-2030)
  • Table 124. Liver Disease Treatment Fatty liver disease. , by Region USD Million (2025-2030)
  • Table 125. Liver Disease Treatment: by Treatment Type(USD Million)
  • Table 126. Liver Disease Treatment Anti-Rejection Drugs/Immunosupressants , by Region USD Million (2025-2030)
  • Table 127. Liver Disease Treatment Chemotherapy Drugs , by Region USD Million (2025-2030)
  • Table 128. Liver Disease Treatment Targeted therapy , by Region USD Million (2025-2030)
  • Table 129. Liver Disease Treatment Vaccines , by Region USD Million (2025-2030)
  • Table 130. Liver Disease Treatment Anti-Viral Drugs , by Region USD Million (2025-2030)
  • Table 131. Liver Disease Treatment IImmunoglobulins , by Region USD Million (2025-2030)
  • Table 132. Liver Disease Treatment Corticosteroids , by Region USD Million (2025-2030)
  • Table 133. South America Liver Disease Treatment, by Country USD Million (2025-2030)
  • Table 134. South America Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 135. South America Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 136. South America Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 137. Brazil Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 138. Brazil Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 139. Brazil Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 140. Argentina Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 141. Argentina Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 142. Argentina Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 143. Rest of South America Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 144. Rest of South America Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 145. Rest of South America Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 146. Asia Pacific Liver Disease Treatment, by Country USD Million (2025-2030)
  • Table 147. Asia Pacific Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 148. Asia Pacific Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 149. Asia Pacific Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 150. China Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 151. China Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 152. China Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 153. Japan Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 154. Japan Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 155. Japan Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 156. India Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 157. India Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 158. India Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 159. South Korea Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 160. South Korea Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 161. South Korea Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 162. Taiwan Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 163. Taiwan Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 164. Taiwan Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 165. Australia Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 166. Australia Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 167. Australia Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 168. Rest of Asia-Pacific Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 169. Rest of Asia-Pacific Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 170. Rest of Asia-Pacific Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 171. Europe Liver Disease Treatment, by Country USD Million (2025-2030)
  • Table 172. Europe Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 173. Europe Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 174. Europe Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 175. Germany Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 176. Germany Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 177. Germany Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 178. France Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 179. France Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 180. France Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 181. Italy Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 182. Italy Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 183. Italy Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 184. United Kingdom Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 185. United Kingdom Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 186. United Kingdom Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 187. Netherlands Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 188. Netherlands Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 189. Netherlands Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 190. Rest of Europe Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 191. Rest of Europe Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 192. Rest of Europe Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 193. MEA Liver Disease Treatment, by Country USD Million (2025-2030)
  • Table 194. MEA Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 195. MEA Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 196. MEA Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 197. Middle East Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 198. Middle East Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 199. Middle East Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 200. Africa Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 201. Africa Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 202. Africa Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 203. North America Liver Disease Treatment, by Country USD Million (2025-2030)
  • Table 204. North America Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 205. North America Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 206. North America Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 207. United States Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 208. United States Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 209. United States Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 210. Canada Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 211. Canada Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 212. Canada Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 213. Mexico Liver Disease Treatment, by Application USD Million (2025-2030)
  • Table 214. Mexico Liver Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 215. Mexico Liver Disease Treatment, by Treatment Type USD Million (2025-2030)
  • Table 216. Research Programs/Design for This Report
  • Table 217. Key Data Information from Secondary Sources
  • Table 218. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Liver Disease Treatment: by Application USD Million (2018-2023)
  • Figure 5. Global Liver Disease Treatment: by Disease Type USD Million (2018-2023)
  • Figure 6. Global Liver Disease Treatment: by Treatment Type USD Million (2018-2023)
  • Figure 7. South America Liver Disease Treatment Share (%), by Country
  • Figure 8. Asia Pacific Liver Disease Treatment Share (%), by Country
  • Figure 9. Europe Liver Disease Treatment Share (%), by Country
  • Figure 10. MEA Liver Disease Treatment Share (%), by Country
  • Figure 11. North America Liver Disease Treatment Share (%), by Country
  • Figure 12. Global Liver Disease Treatment share by Players 2023 (%)
  • Figure 13. Global Liver Disease Treatment share by Players (Top 3) 2023(%)
  • Figure 14. Global Liver Disease Treatment share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 17. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 18. Actavis (United States) Revenue, Net Income and Gross profit
  • Figure 19. Actavis (United States) Revenue: by Geography 2023
  • Figure 20. Aton Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 21. Aton Pharma (United States) Revenue: by Geography 2023
  • Figure 22. Bayer Schering AG (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Bayer Schering AG (Germany) Revenue: by Geography 2023
  • Figure 24. Biotest (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Biotest (Germany) Revenue: by Geography 2023
  • Figure 26. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 27. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 28. Eli Lilly ( United States) Revenue, Net Income and Gross profit
  • Figure 29. Eli Lilly ( United States) Revenue: by Geography 2023
  • Figure 30. Forest Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 31. Forest Laboratories (United States) Revenue: by Geography 2023
  • Figure 32. GlaxoSmithkline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. GlaxoSmithkline (United Kingdom) Revenue: by Geography 2023
  • Figure 34. Gilead Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 35. Gilead Sciences (United States) Revenue: by Geography 2023
  • Figure 36. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 38. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 39. Mylan (United States) Revenue: by Geography 2023
  • Figure 40. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 41. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 42. Global Liver Disease Treatment: by Application USD Million (2025-2030)
  • Figure 43. Global Liver Disease Treatment: by Disease Type USD Million (2025-2030)
  • Figure 44. Global Liver Disease Treatment: by Treatment Type USD Million (2025-2030)
  • Figure 45. South America Liver Disease Treatment Share (%), by Country
  • Figure 46. Asia Pacific Liver Disease Treatment Share (%), by Country
  • Figure 47. Europe Liver Disease Treatment Share (%), by Country
  • Figure 48. MEA Liver Disease Treatment Share (%), by Country
  • Figure 49. North America Liver Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Actavis (United States)
  • Aton Pharma (United States)
  • Bayer Schering AG (Germany)
  • Biotest (Germany)
  • Bristol-Myers Squibb (United States)
  • Eli Lilly ( United States)
  • Forest Laboratories (United States)
  • GlaxoSmithkline (United Kingdom)
  • Gilead Sciences (United States)
  • Merck & Co. (United States)
  • Mylan (United States)
  • Novartis (Switzerland)
Additional players considered in the study are as follows:
Pfizer (United States) , Roche (Switzerland) , Takeda Pharmaceuticals (Japan)
Select User Access Type

Key Highlights of Report


Jan 2024 203 Pages 93 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Liver Disease Treatment Market Quantitative research analysis
Global Liver Disease Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Laboratories (United States), Actavis (United States), Aton Pharma (United States), Bayer Schering AG (Germany), Biotest (Germany), Bristol-Myers Squibb (United States), Eli Lilly ( United States), Forest Laboratories (United States), GlaxoSmithkline (United Kingdom), Gilead Sciences (United States), Merck & Co. (United States), Mylan (United States) and Novartis (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Use of Hybrid Systems For Imaging " is seen as one of major influencing trends for Liver Disease Treatment Market during projected period 2023-2030.
The Liver Disease Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Liver Disease Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Cancer Pain Therapeutics Comprehensive Study by Type (Opioids, Non-Steroidal Anti-Inflammatory Drugs, Others), Application (Related Immunotherapy, Radiotherapy, Chemotherapy, Hormone Therapy), End Us...
$ 3350
Antinuclear Antibody Test Comprehensive Study by Type (Reagents and Assay Kits, Software and Services, Systems), Disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Scler...
$ 3750
Cell Culture Comprehensive Study by Type (Equipment, Consumables), Application (Biopharmaceutical, Cancer Research, Drug Screening & Development, Tissue Engineering & Regenerative Medicine, Others), ...
$ 3750
Coagulation Factors Comprehensive Study by Type (Coagulation Factor VIIa, Coagulation Factor IX, Coagulation Factor IX, Coagulation Factor IX, Coagulation Factor X, Others), Application (Pharmacy, Ho...
$ 3450
Engineered T Cells Comprehensive Study by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor (TCR), Chimeric Antigen Receptor (CAR)), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Me...
$ 3450
Chronic Obstructive Pulmonary Disorder Comprehensive Study by Type (Chronic Bronchitis, Emphysema), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Medication Type (Bronchodi...
$ 3750